Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.


Sci. STKE, 20 February 2007
Vol. 2007, Issue 374, p. pe8
[DOI: 10.1126/stke.3742007pe8]


Meeting Report: Targeting the Kinome—20 Years of Tyrosine Kinase Inhibitor Research in Basel

Lana Bozulic1, Pier Jr Morin1, Tony Hunter2, and Brian A. Hemmings1*

1Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland.
2Salk Institute for Biological Studies, La Jolla, California, USA.

A report on the "Targeting the Kinome" meeting, Basel, Switzerland, 4 to 6 December 2006.

Abstract: With basic and pharmaceutical researchers, chemists, pharmacologists, and clinicians, the Targeting the Kinome meeting brought together a tremendous group of scientists to discuss the past, present, and future of protein kinase research, with a special emphasis on cancer therapy development. The topics ranged from the kinases themselves as drug targets through the interactions that the actions of these enzymes promote, to the physiological and pathological processes they regulate. Attendees gained insight into drug development, as well as increased understanding of how normal cellular processes are subverted during oncogenesis, which may lead to new targets for intervention.

*Corresponding author. E-mail: brian.hemmings{at}

Citation: L. Bozulic, P. J. Morin, T. Hunter, B. A. Hemmings, Meeting Report: Targeting the Kinome—20 Years of Tyrosine Kinase Inhibitor Research in Basel. Sci. STKE 2007, pe8 (2007).

Read the Full Text

To Advertise     Find Products

Science Signaling. ISSN 1937-9145 (online), 1945-0877 (print). Pre-2008: Science's STKE. ISSN 1525-8882